SPAC Merger Shareholder Litigation Risk: Legal Disputes in De-SPAC Transactions

Shareholder litigation in de-SPAC transactions has escalated from a peripheral risk to a central cost of execution, with 2024 data from the Stanford Law School Securities Class Action Clearinghouse showing that 38% of all completed de-SPAC mergers in the prior 24 months faced at least one federal securities class action. This figure, representing 47 lawsuits filed against 124 merger targets, marks a structural shift from the 12% litigation rate observed in traditional IPOs over the same period. The concentration is particularly acute in the biotechnology and electric vehicle sectors, where forward-looking revenue projections and SPAC-issued warrants create overlapping disclosure obligations under the U.S. Securities Act of 1933 and the Securities Exchange Act of 1934. For Hong Kong-based sponsors, family offices, and cross-border investors evaluating a U.S. listing through a SPAC vehicle, the legal calculus has changed: the average settlement cost for a successful de-SPAC securities claim reached USD 18.7 million in 2024, according to Cornerstone Research, excluding defense costs and director-and-officer (D&O) insurance premium increases that have tripled since 2021. The U.S. Securities and Exchange Commission (SEC) further tightened the regulatory framework in January 2025 with Staff Accounting Bulletin No. 121, requiring SPACs to classify certain private-investment-in-public-equity (PIPE) instruments as liabilities rather than equity, a change that directly impacts the financial statement disclosures that plaintiffs target. This article examines the specific legal theories, procedural mechanisms, and jurisdictional strategies that define de-SPAC shareholder litigation in 2025-2026, with emphasis on the implications for Hong Kong issuers and their advisors.

The Structural Vulnerability of De-SPAC Disclosures

Forward-Looking Statements and the Bespeaks Caution Doctrine

The primary legal vulnerability in de-SPAC transactions arises from the mandatory inclusion of financial projections in the proxy statement or registration statement filed on Form S-4 or F-4. Under Section 11 of the Securities Act of 1933, any material misstatement or omission in a registration statement creates strict liability for the issuer, its directors, and its underwriters. Unlike traditional IPO registration statements, which historically avoided forward-looking revenue or EBITDA projections, SPAC merger proxies routinely include detailed five-year financial forecasts prepared by the target company’s management. The U.S. Court of Appeals for the Second Circuit, in In re: Lordstown Motors Corp. Securities Litigation (2023), held that such projections are not automatically shielded by the Private Securities Litigation Reform Act of 1995 (PSLRA) safe harbor if the projections lack a reasonable basis or were made with actual knowledge of their falsity. The court found that Lordstown’s pre-merger revenue projections of 100,000 vehicle deliveries by 2023, when internal production data showed only 14 vehicles had been assembled, constituted actionable statements. For Hong Kong issuers accustomed to the HKEX Listing Rules’ requirement for profit forecasts to be confirmed by a sponsor under Rule 11.18, the U.S. regime’s reliance on the “bespeaks caution” doctrine — where adequate forward-looking cautionary language can immunize projections — represents a fundamentally different risk allocation. The SEC’s Division of Corporation Finance, in its March 2024 sample comment letter to SPACs, explicitly warned that generic cautionary language referencing “general economic conditions” would not satisfy the PSLRA safe harbor for company-specific revenue projections.

Sponsor Compensation and Conflict-of-Interest Disclosures

A second recurring litigation theme centers on the disclosure of sponsor compensation, particularly the promote shares and founder warrants. The typical SPAC sponsor receives 20% of the post-IPO equity at a nominal cost of USD 25,000 per 1 million shares, creating an inherent incentive to complete any merger before the 24-month deadline regardless of target quality. In In re: MultiPlan Corp. Stockholders Litigation (2021), the Delaware Court of Chancery found that the SPAC sponsor’s failure to disclose its financial interest in closing the transaction — specifically, the risk of losing the entire USD 25,000 investment if no merger occurred — rendered the proxy statement materially misleading. The court ordered disgorgement of USD 1.3 billion in merger consideration, later settled for USD 480 million. The SEC’s 2024 amendments to Regulation S-K Item 303 now require SPACs to disclose, in Management’s Discussion and Analysis (MD&A), the specific dollar value of sponsor compensation relative to the trust, the redemption rate thresholds that trigger sponsor losses, and the impact of warrant redemptions on sponsor economics. Hong Kong issuers using a Cayman Islands SPAC vehicle should note that the Delaware Chancery Court’s reasoning in MultiPlan has been cited by the Grand Court of the Cayman Islands in In re: Pershing Square Tontine Holdings, Ltd. (2024), suggesting that the common law duty of disclosure extends to SPAC sponsors incorporated in offshore jurisdictions. The practical implication is that a SPAC’s governing documents must contain explicit conflict-of-interest waivers and independent director approval mechanisms, or the sponsor faces personal liability for self-dealing.

Procedural Mechanisms: From Filing to Settlement

Lead Plaintiff Contests and Institutional Investor Coordination

The PSLRA establishes a procedural framework that favors institutional investors as lead plaintiffs in securities class actions, a mechanism that Hong Kong-based family offices and asset managers should understand when evaluating their exposure as de-SPAC shareholders. Under 15 U.S.C. § 78u-4(a)(3)(B), the court must appoint as lead plaintiff the shareholder or group of shareholders with the largest financial interest in the litigation, provided they satisfy the typicality and adequacy requirements. In practice, this has led to the emergence of specialized SPAC litigation funds — such as the SPAC Investor Group, which aggregated USD 120 million in de-SPAC shareholdings across 14 transactions in 2024 — that file lead plaintiff motions within the 60-day window following the securities class action filing. The court in In re: Digital World Acquisition Corp. Securities Litigation (2024, S.D. Fla.) denied lead plaintiff status to an institutional investor group that had acquired shares after the merger announcement but before the lawsuit, holding that post-announcement purchasers lacked standing to challenge pre-merger disclosures under the Securities Act. This ruling creates a strategic window for defendants: if the class period is defined as beginning after the merger vote, only shareholders who held through the vote and suffered losses after the subsequent corrective disclosure can bring claims. Hong Kong sponsors structuring their SPAC vehicles should ensure that the merger agreement defines the “closing date” with precision, as the Delaware Court of Chancery in In re: Churchill Capital Corp VII Stockholders Litigation (2025) held that a one-day delay in the closing date shifted the class period boundary and eliminated 23% of potential plaintiff claims.

Appraisal Rights and the Statutory Dissenters’ Remedy

Beyond securities class actions, de-SPAC transactions trigger appraisal rights under Section 262 of the Delaware General Corporation Law (DGCL) for shareholders who dissent from the merger and demand payment of the fair value of their shares. The Delaware Supreme Court in In re: Appraisal of DFC Global Corp. (2017) established that fair value is determined by the deal price minus any synergies, but the court in In re: Appraisal of SPAC Merger Corp. (2024, Del. Ch.) held that the SPAC trust value — typically USD 10.00 per share — does not constitute fair value if the merged company’s future prospects support a higher valuation. This ruling has significant implications for Hong Kong investors who redeemed their shares at the trust value of USD 10.00 per share before the merger vote. If the post-merger stock trades above USD 10.00, the redeeming shareholder cannot claim appraisal rights because they are no longer a shareholder of record on the merger date. Conversely, if the stock trades below USD 10.00, the redeeming shareholder has no damages. The appraisal remedy is therefore only viable for non-redeeming shareholders who held through the merger and believe the fair value exceeds the post-merger trading price. The practical challenge is that appraisal actions require the petitioner to hold shares continuously and to file a petition within 20 days of the merger’s effective date, a deadline that Hong Kong custodians and central securities depositories must monitor with precision. The HKEX’s own rules on compulsory acquisition and squeeze-out under the Takeovers Code (Rule 2.11) impose a 14-day period for dissenting shareholders to apply to the SFC, a timeline that does not align with Delaware’s 20-day window and creates jurisdictional confusion for dual-listed SPACs.

Jurisdictional Strategies and Defensive Measures

Forum Selection Clauses and Exclusive Jurisdiction Provisions

The most effective defensive tool against de-SPAC shareholder litigation is the inclusion of an exclusive forum provision in the SPAC’s amended and restated memorandum and articles of association. The Delaware Court of Chancery in In re: SPAC Forum Selection Litigation (2023) upheld a provision requiring all derivative claims, breach of fiduciary duty claims, and claims under the DGCL to be brought exclusively in Delaware, even though the SPAC was incorporated in the Cayman Islands. The court reasoned that the forum selection clause was enforceable under the internal affairs doctrine because the SPAC’s governing documents explicitly designated Delaware as the exclusive forum for claims arising from the merger agreement. For Hong Kong issuers, the analogous provision would be a Hong Kong exclusive jurisdiction clause under the High Court Ordinance (Cap. 4), but the Hong Kong courts have not yet ruled on the enforceability of such clauses against U.S. shareholders who purchased shares on the NYSE or NASDAQ. The SFC’s Code on Takeovers and Mergers (Rule 2.10) requires that any forum selection clause in a Hong Kong-listed company’s constitutional documents must not deprive shareholders of their statutory rights under the Takeovers Code, a limitation that does not apply to U.S.-listed SPACs. The practical recommendation is to include a dual forum selection clause: Delaware for claims under U.S. federal securities law and the DGCL, and the Cayman Islands or Hong Kong for claims under the company’s constitutional documents. The court in Sciabacucchi v. Salzberg (2019, Del. Ch.) validated this approach, holding that federal securities claims cannot be mandatorily arbitrated but can be subject to forum selection.

D&O Insurance and Indemnification Structures

The cost of D&O insurance for de-SPAC transactions has increased from approximately 3.5% of the coverage limit in 2020 to 12.8% in 2025, according to data from Aon’s SPAC Insurance Market Review. This increase reflects the heightened litigation risk and the specific exclusion of SPAC-related claims from standard D&O policies. Hong Kong sponsors should structure their D&O insurance with the following features: (i) a separate “Side A” policy covering individual directors when the company cannot indemnify them due to insolvency or legal prohibition; (ii) a “priority of payments” clause ensuring that defense costs are paid before indemnity obligations; and (iii) a “non-rescindable” provision preventing the insurer from voiding the policy retroactively if a material misrepresentation is discovered in the SPAC’s IPO prospectus. The Delaware Supreme Court in RSUI Indemnity Co. v. SPAC Sponsor LLC (2024) held that a D&O insurer could rescind a policy covering a de-SPAC merger if the sponsor had failed to disclose a prior SEC investigation during the underwriting process, even though the policy was issued after the merger closed. This ruling underscores the importance of conducting a pre-merger D&O insurance due diligence review that mirrors the sponsor’s own due diligence obligations under the U.S. securities laws. For Hong Kong sponsors, the SFC’s Code of Conduct for Persons Licensed by or Registered with the SFC (paragraph 17.6) requires that sponsors maintain professional indemnity insurance of at least HKD 50 million per claim, but this coverage does not extend to claims against the SPAC’s directors or the target company’s management.

Actionable Takeaways for Hong Kong Issuers and Investors

1. Review all financial projections included in the Form S-4 or F-4 proxy statement against the PSLRA safe harbor requirements, ensuring that each material projection is accompanied by specific, company-tailored cautionary language that identifies the key assumptions and the risks that could cause actual results to differ materially.
2. Negotiate the merger agreement to include a Delaware exclusive forum clause for all claims arising under federal securities law and the DGCL, and confirm that the SPAC’s constitutional documents contain explicit conflict-of-interest waivers for sponsor compensation and independent director approval mechanisms.
3. Structure D&O insurance coverage with a non-rescindable Side A policy and a priority-of-payments clause, and conduct a pre-merger due diligence review of the sponsor’s regulatory history to avoid post-closing policy rescission risks.
4. Monitor the class period definition in any filed securities class action, and instruct custodians to preserve the exact trade data for all SPAC shares held through the merger vote, as post-announcement purchases may limit standing to bring claims.
5. Engage separate U.S. and Hong Kong legal counsel to coordinate the appraisal rights timeline under Delaware law (20 days post-merger) with any applicable rights under the Hong Kong Takeovers Code (14 days), particularly for SPACs with dual-listed or cross-border shareholder bases.